Ticker Details
Corbus Pharmaceuticals Holdings, Inc. Common Stock Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
IPO Date:	November 1, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$183.04M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.31 | 3.84%
Avg Daily Range (30 D):	$0.34 | 3.78%
Avg Daily Range (90 D):	$0.27 | 3.03%

Institutional Daily Volume
Avg Daily Volume:	.3M
Avg Daily Volume (30 D):	.2M
Avg Daily Volume (90 D):	.22M

Trade Size
Avg Trade Size (Sh.):	59
Avg Trade Size (Sh.) (30 D):	68
Avg Trade Size (Sh.) (90 D):	63

Institutional Trades
Total Institutional Trades:	446
Avg Institutional Trade:	$1.77M
Avg Institutional Trade (30 D):	$2.13M
Avg Institutional Trade (90 D):	$1.22M
Avg Institutional Trade Volume:	.04M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.06M
Avg Closing Trade (30 D):	$2.13M
Avg Closing Trade (90 D):	$2.13M
Avg Closing Volume:	45.81K

News

Feb 12, 2026 @ 1:00 PM Corbus Pharmaceuticals to Present at the 36th Annu... Source: Not Specified

Oct 31, 2025 @ 6:40 AM Corbus Pharmaceuticals Announces Pricing of Public... Source: Globe Newswire

Oct 31, 2025 @ 6:40 AM Corbus Pharmaceuticals Announces Pricing of Public... Source: Sean Moran

Oct 18, 2025 @ 7:00 AM Corbus Pharmaceuticals Presents CRB-701 Robust Cli... Source: Corbus Pharmaceuticals

Jul 10, 2025 @ 5:00 PM Cannabinoid Agonist Clinical Trial Pipeline Appear... Source: Delveinsight

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-5.9	$-1.17	$-5.9
Diluted EPS	$-5.9	$-1.17	$-5.9
Revenue	$5.53M	$1.41M	$5.53M
Gross Profit
Net Income / Loss	$-78.54M	$-20.56M	$-78.54M
Operating Income / Loss	$-85.31M	$-21.97M	$-85.31M
Cost of Revenue
Net Cash Flow	$11.29M	$1.51M	$11.29M
PE Ratio

Splits
Feb 14, 2023	1:30